Orville Bovenschen, who serves as President of Canadian Cannabis for Village Farms International, Inc. (NASDAQ:VFF), sold 50,000 common shares of the company on March 25, 2026. The disposition was carried out through several open-market transactions with execution prices spanning $2.89 to $2.90 per share, producing aggregate proceeds of $144,500, according to the company filing.
The Form 4 filing with the Securities and Exchange Commission indicates that following these trades Bovenschen directly holds 0 shares of Village Farms International. The insider sale was disclosed publicly via the regulatory filing.
At the time the sale was noted, VFF shares were trading at $2.73, a level that represents a 25% decline year-to-date while still reflecting a 308% increase over the last twelve months. The stock’s current price-to-earnings multiple stands at 15.19 and the company’s market capitalization is reported at $317 million.
Market research from InvestingPro cited in the filing characterizes the share price as appearing undervalued by its Fair Value assessment. Analysts contributing to that assessment have established price targets for VFF in a range from $4.25 to $5.50. The InvestingPro analysis also highlights the company’s financial-health score of 3.03, a rating described as "GREAT," and notes that subscribers can access more than 10 additional ProTips and an expanded Pro Research Report covering VFF along with over 1,400 other U.S. equities.
Separately, Village Farms International reported fourth-quarter 2025 results that fell short of analyst expectations. The company posted earnings per share of $0.01, missing the consensus forecast of $0.02. Revenue for the quarter was $49.6 million, below the anticipated $60.88 million. Despite the shortfall in the fourth quarter, the company recorded a full-year performance that set a company record for financial results. Nonetheless, the quarter’s earnings and revenue misses prompted a negative reaction from market participants.
Investors and stakeholders have been reacting to the combination of the insider sale, the Q4 earnings and revenue miss, and the divergence between the current share price and analyst price targets. The regulatory Form 4 disclosure documents the insider transaction; the company’s reported financials provide the contemporaneous operating context.